Cargando…

TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis

Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib and entrectinib provide rationale for next-genera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medford, Arielle J., Oshry, Lauren, Boyraz, Baris, Kiedrowski, Lesli, Menshikova, Sofia, Butusova, Anna, Dai, Charles S., Gogakos, Tasos, Keenan, Jennifer C., Occhiogrosso, Rachel H., Ryan, Phoebe, Lennerz, Jochen K., Spring, Laura M., Moy, Beverly, Ellisen, Leif W., Bardia, Aditya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893401/ https://www.ncbi.nlm.nih.gov/pubmed/36743521 http://dx.doi.org/10.1177/17588359231152844

Ejemplares similares

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2023)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma
por: Wang, Hejing, et al.
Publicado: (2023)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
por: Medford, Arielle J., et al.
Publicado: (2019)

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
por: Spring, Laura M., et al.
Publicado: (2017)

Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer()()
por: Choi, Yuri, et al.
Publicado: (2018)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

NTRK1/TrkA Activation Overrides the G(2)/M-Checkpoint upon Irradiation
por: Hassiepen, Christina, et al.
Publicado: (2021)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma
por: Macerola, Elisabetta, et al.
Publicado: (2022)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
por: Klink, Andrew J., et al.
Publicado: (2022)

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2021)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
por: Hsiao, Susan J., et al.
Publicado: (2019)

NTRK1/TrkA Signaling in Neuroblastoma Cells Induces Nuclear Reorganization and Intra-Nuclear Aggregation of Lamin A/C
por: Funke, Lukas, et al.
Publicado: (2021)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

EPEN-25. EXCEPTIONAL CLINICAL AND IMAGING RESPONSE TO TRK-INHIBITION IN A PATIENT WITH SUPRATENTORIAL EPENDYMOMA HARBORING NTRK2 GENE FUSION
por: Mangum, Ross, et al.
Publicado: (2020)

Change of tRNA identity leads to a divergent orthogonal histidyl-tRNA synthetase/tRNA(His) pair
por: Yuan, Jing, et al.
Publicado: (2011)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
por: Konicek, Bruce W., et al.
Publicado: (2018)

Expression of the neurotrophic tyrosine kinase receptors, ntrk1 and ntrk2a, precedes expression of other ntrk genes in embryonic zebrafish
por: Hahn, Katie, et al.
Publicado: (2020)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
por: Durzyńska, Monika, et al.
Publicado: (2023)

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
por: Jacob, Saya L., et al.
Publicado: (2020)

Cognitive Computing to Guide Molecular‐Based Therapy Selection: Steps Forward amid Abundant Need
por: Ellisen, Leif W.
Publicado: (2018)

A wound-healing program is hijacked to promote cancer metastasis
por: Ellisen, Leif W.
Publicado: (2017)

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022)

Case 40-2020: A 24-Year-Old Man with Headache and Covid-19
por: Heller, Howard M., et al.
Publicado: (2020)

Patterns of Polysubstance Use Among Non-Hispanic White and American Indian/Alaska Native Adolescents: An Exploratory Analysis
por: Kiedrowski, Lee, et al.
Publicado: (2019)

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
por: Gomez, Daniel Richard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mejpli98ufv201smdg4k3ln5kc